Coronary disease & ACSResearch article
Short-term outcomes of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction: A randomized pilot study
- multicenter open-label pilot study
- 1:1 randomized
Authors' conclusion
Although no significant difference in ischemic events was observed between the novel concept of ticagrelor monotherapy and DAPT, safety cannot be confirmed given the small number of events. Additionally, there was a tendency for a reduction in clinically relevant non-access site bleeding events.
Study context
- Population
- ST-elevation myocardial infarction (STEMI) patients directly after primary percutaneous coronary intervention (PCI)STEMI patients randomized
- Participants
- 200 participants
- Comparison
- experimental group vs control group
- experimental groupn = 99
- control groupn = 101reference
Main finding
As reported in the abstract
Major adverse cardiac and cerebral events (MACCE) · 3 months
Hazard ratio
1.54
95% CI 0.26–9.24
By group
experimental group vs control group
HR 1.54 (95% CI 0.26–9.24)
Safety
| Outcome | experimental group | control group | HR (95% CI) | |
|---|---|---|---|---|
| Clinically relevant bleeding · 3 months | 4.2% | 8.9% | 0.46 (0.14–1.48) | |
| Clinically relevant non-access site bleeding · 3 months | 2.0% | 7.9% | 0.25 (0.05–1.19) | |
| 0.050.21520Hazard ratio (log scale) |
Original publication
Short-term outcomes of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction: A randomized pilot study. Am Heart J. Published 28 April 2026. doi:10.1016/j.ahj.2026.107460
Summarised from the published abstract; every number is checked against it